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INTRODUCTION
Swine infl uenza virus (SIV) infections are a common cause of  bronchointerstitial 
pneumonia and respiratory disease in pigs [1]. Although the mortality of  SIV infected 
pigs is usually low, morbidity may approach 100 % leading to signifi cant economic 
losses in the swine industry. SIVs are classifi ed to the genus infl uenza A of  the family 
Orthomyxoviridae, containing eight segments of  a single-stranded RNA genome of  
negative polarity [2]. Due to their segmented genome, infl uenza A viruses undergo 
infrequent antigenic shift or reassortment, leading to generation of  novel infl uenza A 
viruses. Epithelial cells in the lower part of  the swine respiratory tract have receptors 
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Research article
The 2009 outbreak of  H1N1 infl uenza A viruses in humans underscored the importance 
of  pigs in infl uenza A virus evolution and the emergence of  novel viruses with pandemic 
potential. In addition, infl uenza A virus infections continued to cause production losses 
in the agricultural industry resulting in a signifi cant drop of  profi t. The primary method 
to control infl uenza A virus infections in pigs is through vaccination. Previously we 
demonstrated that two doses of  an elastase-dependent live attenuated swine infl uenza 
virus administered by either the intratracheal or intranasal route can provide a high 
degree of  protection in pigs against challenge with both homologous and different 
heterologous swine infl uenza viruses. Here we report the protection effi cacy of  a 
single dose elastase-dependent live attenuated swine infl uenza virus administered by 
the intranasal route against challenge with homologous subtypic H1N1 2009 pandemic 
swine-like infl uenza virus. Protection was observed in the absence of  neutralizing 
antibodies specifi c for H1N1 2009 in sera.
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for both avian and mammalian infl uenza viruses [3], thus pigs could potentially serve as 
“mixing vessels” for the generation of  new reassortant strains with pandemic capacity. 
This has been documented for the emerged H1N1 2009 infl uenza A virus that was 
result of  subsequent reassortment of  swine infl uenza viruses in 2009 [4]. This H1N1 
2009 virus contains six genes of  the North American swine triple reassortant lineage 
with the M and NA acquired from the Eurasian swine lineage H1N1. In addition, H1N1 
2009 viruses are characterized by increased human transmission and high pathogenicity 
in young adults constituting a signifi cant public health concern [4,5]. The emergence of  
the H1N1 2009 infl uenza A virus demonstrated that the fl ow of  infl uenza virus genes 
between swine and humans is bidirectional [4].  Consequently, effective control and 
prevention of  SIV infections are required for both human and animal health. 
The most common method for control of  swine infl uenza virus infections in swine 
farms is through vaccination. Currently used vaccines against swine infl uenza are 
inactivated whole virus or split virus preparations for intramuscular administration. 
These vaccines contain antigens from representatives of  the H1N1, H1N2 and H3N2 
subtypes in combination with an oil adjuvant. Application of  these vaccines reduces 
the severity of  disease but does not provide consistent protection from infection [6,7]. 
These vaccines induce little or no heterologous immunity between infl uenza subtypes 
or genetically different viruses within subtype [8]. In contrast to inactivated vaccines, 
live attenuated infl uenza vaccines (LAIV) delivered to mucosal surfaces induce immune 
responses at the site of  natural infection and heterologous immunity [9,10]. Live 
attenuated infl uenza vaccines also have the potential to induce broad cell-mediated and 
humoral immune responses which could provide better protection against antigenically 
distinct infl uenza viruses. Currently, LAIV are available for human [11] and equine 
species [12]. Despite several reports demonstrating the potential of  LAIV to control 
infl uenza in pigs [9,13] there are currently no commercially available LAIV for pigs used 
anywhere in the world. 
It was previously demonstrated that an elastase-dependent LAIV R345V derived from 
A/Sw/Saskatchewan/18789/02 (H1N1) (SIV/Sk02) is attenuated, immunogenic 
and protective in pigs after two intratracheal (IT) or intranasal (IN) administrations 
[10,13,14]. Attenuation of  this infl uenza virus in pigs was achieved by converting the 
original HA cleavage site from a trypsin-sensitive motif  to an elastase-sensitive motif  
[15]. This virus was demonstrated to be able to protect pigs against homologous H1N1 
SIV as well as to provide partial protection against heterologous H3N2 SIV infection 
[10,13]. In addition, it was demonstrated that two vaccinations administered either 
by the intratracheal or intranasal route induced protection against pandemic A/Sw/
Manitoba/MAFRI32/2009 H1N1 (MAFRI09) in pigs [14]. Intranasal vaccination is 
a more practical way of  immunization and has application to mass herd vaccination 
since it enables the use of  smaller volumes and delivery of  antigens mimicking natural 
infection to provide stronger immune responses [16,17]. In this study, a single intranasal 
administration of  an elastase-dependent attenuated infl uenza A virus was evaluated for 
the ability to protect pigs against H1N1 2009 challenge.
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MATERIALS AND METHODS
Cells, viruses and vaccine 
Madin-Darby canine kidney (MDCK) cells were cultured in minimal essential medium 
(MEM) supplemented with 10% fetal bovine serum (FBS). The H1N1 mutant virus 
SIV/Sk-R345V (R345V) used in this study was generated as previously described [15]. 
This virus contained a modifi ed HA cleavage site which is only sensitive to human 
neutrophil elastase. Wild type H1N1 2009 virus used for a challenge purposes was A/
Sw/Manitoba/MAFRI32/2009 H1N1 (MAFRI09). Propagation and titration of  these 
viruses was described previously [13,14].
Experimental design and sampling
All study procedures and animal care activities were conducted at the National Centre 
for Foreign Animal Disease, Canadian Food Inspection Agency (NCFAD-CFIA), 
Winnipeg, Canada. The entire animal work was carried out in compliance with Canadian 
Council on Animal Care guidelines and was approved by the Animal Care Committee 
at the Canadian Science Centre for Animal and Human Health.
Eleven, four week old pigs were obtained from a local high health pig farm in Manitoba 
(Canada) and housed at the NCFAD-CFIA. All pigs were Duroc breed and SIV 
serologically negative prior to the experiments. Animals were randomly selected and 
divided into two groups. Veterinarian and technical staff  performing vaccination, 
challenge, daily monitoring and necropsies were blinded for experimental groups. Pigs 
assigned to group 1 (n=5) were vaccinated with 1 ml MEM containing 1 x 108 plaque 
forming units (PFU) of  the R345V, while pigs assigned to group 2 (n=6) served as 
non-vaccinated controls (Table 1.). Pigs were vaccinated by the intranasal route (0.5ml/
nostril) following seven days period of  acclimatization. After vaccination with R345V 
pigs were monitored for fi ve consecutive days for the presence of  SIV characteristic 
clinical signs. Consistent with previous observations [15], vaccinated pigs did not show 
any clinical signs related to SIV infections.
Table 1. Experimental group assignment and study design. Eleven animals were randomly 
assigned into two groups (Group 1 [n=5] and Group 2 [n=6]). Animals in both groups 
were vaccinated intranasally with either R345V or MEM (control). Two weeks following 
vaccination animals in both groups were challenged intranasally with 2009 H1N1 SIV and 
euthanized 5 days post challenge.
Group (#N) Vaccination Dose Route Challenge 
1. (5) R345V 1ml 
(1 x 10
8
 pfu/ml)   Intranasal
SIV/MAFRI 2009
H1N1
2. (6) MEM 1ml Intranasal SIV/MAFRI 2009H1N1
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Fifteen days after the vaccination, pigs in both groups were challenged intranasally with 
106 tissue culture infectious doses (TCID50) of  MAFRI09 in a 1 ml volume of  MEM. 
Following the H1N1 2009 challenge, all pigs were monitored for fi ve consecutive 
days for the presence of  fever and SIV characteristic clinical signs. At the end of  
the observation period (day 20) all pigs in both experimental groups were humanely 
euthanized with a lethal dose of  pentobarbital sodium (Euthanyl® 250mg/ml; Bimeda-
MTC Animal Health Inc, Canada) and subjected to necropsy. At necropsy, lungs were 
removed, evaluated and scored for the presence of  SIV characteristic gross lesions. 
The percentage of  the areas affected with pneumonia was estimated visually for each 
lung lobe. The total percentage for the entire lung was calculated based on weight 
proportions of  each lung lobe to the total lung volume [18]. 
Sera were collected from the pigs prior and after vaccination (days -7, 0, 15) and at 
necropsy (day 20). Nasal swabs were taken prior to challenge and every day for fi ve 
consecutive days post challenge. At necropsy, tissue samples from right apical, cardiac 
and diaphragmatic lobes were collected for histopathology evaluation and virus 
isolation.  
 
Evaluation of viral loads
Lung tissue and nasal swab samples were processed as previously described [15]. Viral 
RNA was isolated from swabs and 10% lung homogenates using an RNeasy Mini Kit 
(Qiagen; Cat #74106) according to the manufacturer’s instructions. Viral loads in nasal 
swabs and lung homogenates were determined by a real-time (RT-PCR) assay specifi c 
for the infl uenza A virus matrix (M1) gene [19] with primers and probes that were 
modifi ed to enhance detection of  pandemic swine-like H1N1 2009 [20-22]. In addition, 
the levels of  infectious virus from lung samples were determined by virus isolation on 
MDCK cells as previously described [13,15].
Evaluation of antibody responses
Infl uenza A virus specifi c antibodies in serum were detected using a competitive ELISA 
(cELISA) specifi c for the infl uenza A virus nucleoprotein (NP) [23] as well as IDEXX 
HerdChek SIV Test Kit (IDEXX Laboratories, Westbrook ME). A virus neutralization 
test (VNT) was conducted in 96-well microtiter plates (Corning Incorporated, NY), 
according to methods described in “WHO Manual on Animal Infl uenza Surveillance 
and Diagnosis” [24]. Sera were heat treated, serially diluted, each serial dilution mixed 
with equal volumes of  100 TCID50 of  MAFRI09 and then incubated at 37°C for 
30 min. The mixtures were then transferred onto a confl uent monolayer of  MDCK 
cells prepared on 96-well fl at-bottom plates (Corning Incorporated, NY) and incubated 
at 37°C and 5% CO2 for 96 h. After 4 days incubation, infected cells were fi xed with 
10% formalin and immunostaining was performed to visualize infl uenza infected cells. 
The neutralization titer was expressed at the highest dilution of  serum that prevented 
viral cytopathic effect (CPE). 
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Histopathology and Immunohistochemistry (IHC)
Tissue samples of  right apical, cardiac and diaphragmatic lung lobes were collected 
from all 11 animals at 5 days post challenge.  Additional samples of  lung were 
collected from other areas of  lungs if  additional lesions were observed during post 
mortem examination.  Tissue samples were fi xed in 10% neutral phosphate buffered 
formalin, routinely processed and stained with hematoxylin and eosin (H&E) for 
histopathologic examination. Visualisation of  infl uenza specifi c antigens in lung tissues 
by immunohistochemistry (IHC) was performed as previously described [14]. Positive 
staining for Infl uenza A virus nucleoprotein was graded according to amount of  antigen 
detected in the lung. Board certifi ed pathologist examined all slides and was blinded for 
experimental groups.
Statistics
Statistical analysis of  macroscopic, microscopic lesions, antibody and virus titers were 
performed using GraphPad Prism5 statistical software (GraphPad Software Inc, CA, 
US). Differences between medians in two groups (vaccinated vs. unvaccinated) in each 
assay were determined using a Mann-Whitney nonparametric t-test.  For statistical 
comparison of  virus shedding from upper respiratory tract between vaccinated and 
non-vaccinated challenged pigs (RT-PCR from nasal swabs) standard two-way ANOVA 
which compares the differences among group means with the pooled standard deviations 
of  the groups was used. If  the median or mean (ANOVA) values of  at least one group 
differed from others with a P < 0.05 they were considered statistically signifi cant.
 
RESULTS
Clinical signs and gross pathology
Fifteen days after the single intranasal immunization, pigs were challenged intranasally 
with H1N1 MAFRI09 and observed for 5 days. At the end of  observation period (day 
20) all 11 pigs were euthanized and necropsies were performed. During the fi ve-day 
observation period no apparent clinical signs with respect to respiratory distress and 
nasal discharge were observed in both experimental groups (groups 1 and 2). Clinical 
disease following A/Sw/Manitoba/MAFRI32/2009 H1N1 challenge was very similar 
to that observed following A/Mexico/InDRE4487/2009 H1N1 challenge [25]. 
All unvaccinated control pigs following H1N1 2009 challenge developed lesions 
typical for SIV  (Fig 1. B and C) characterized by sharply demarcated, purple coloured 
consolidated areas most prevalent in the cardiac and apical lobes (median score of  9.0). 
In contrast, 3 out of  5 pigs vaccinated with R345V by intranasal administration and 
challenged with MAFRI09, had detectable minimal gross lesions corresponding to SIV 
infections (median score of  1.5). Although lung lesions were seen in pigs vaccinated 
and challenged with H1N1 2009 (Fig 1. A), the severity and distribution of  lesions 
was signifi cantly reduced compared to unvaccinated controls (P=0.043)(Fig. 1D). These 




Lung sections from apical, cardiac and diaphragmatic lobes were evaluated for microscopic 
lesions at fi ve days post challenge. In general, for both control and vaccinated groups, 
the most prominent lesions were observed in the cardiac lobes. In the non-vaccinated 
control pigs, all animals showed moderate to severe lesions that were multifocal and 
lobular. Lesions were characterized by necrotizing bronchiolitis with necrotic debris 
and neutrophils in bronchiolar lumina. There wеrе perivascular, peribronchiolar and 
interstitial infi ltrates of  lymphocytes and plasma cells with atelectasis of  alveoli adjacent 
to the bronchiolar lesions (Fig. 2A). In some areas alveoli contained exudates composed 
of  edema fl uid and neutrophils. Multifocally, alveolar septa were hypercellular. In 4 out 
of  5 vaccinated animals there were occasional mild peribronchiolar and/or interstitial 
infi ltrates of  lymphocytes and plasma cells (Fig. 2C). In one vaccinated animal there 
were 2 small focal areas of  bronchiolitis and atelectasis in the section from the cardiac 
lobe (Fig. 2E). 
Using immunohistochemistry, sections were evaluated for the presence of  infl uenza A 
virus specifi c antigen. In all of  non-vaccinated control pigs, there was extensive positive 
immunostaining within bronchiolar epithelial cells as well as within cells of  the alveolar 
Figure 1. Necropsy (A) Representative pig lungs from vaccinated (R345V) and H1N1 2009 
challenged group; Apical and cardiac lung lobes [dorsal (B) and ventral (C) view] from 
representative of  unvaccinated and H1N1 2009 challenged group; Gross lung pathology scores 
(D) Lungs from vaccinated and unvaccinated pigs were assessed for gross pathology 5 days 
following H1N1 2009 challenge. Differences between vaccinated (R345V) pigs compared to 
control (MEM) pigs were determined using a Mann-Whitney nonparametric t-test P < 0.05. The 
bar represents the median.
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walls which were identifi ed by morphology to be primarily macrophages with occasional 
pneumocytes (Fig. 2B). Within the vaccinated group, viral antigen could not be detected 
in 4 out of  5 animals (Fig. 2D). In one vaccinated animal there were 2 small areas of  positive 
immunostaining in the lung section from the cardiac lobe which included primarily 
Figure  2. Histopathology and immunohistochemistry fi ndings at 5 days post infection. Lung 
section from a non-vaccinated (challenge) control pig: (A) (H&E) with extensive atelectasis, 
alveolitis and bronchiolitis (arrows). (B) (IHC) extensive positive immunostaining within 
bronchioles (arrowhead), neutrophilic exudates (*) and alveolar cells (arrow). Lung section 
representative of  4 out of  5 vaccinated pigs following challenge: (C) (H&E) with mild 
peribronchiolar lymphoplasmacytic infi ltrate (arrow) and (D) (IHC) viral antigen could not 
be detected. Lung section from one vaccinated pig: (E) (H&E) with occasional bronchiolitis 
(arrows) and (F) (IHC) a focal area of  positive immunostaining corresponds to the presence of  
a lesion (arrow).  Bar = 200 μm in all fi gures.
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bronchiolar epithelium and a few cells within alveolar walls with the morphological 
appearance of  macrophages (Fig. 2F).  Both nuclear and cytoplasmic immunostaining 
pattern was observed within the bronchiolar epithelial cells in control animals as well as 
in the one vaccinated animal where staining was observed.  Furthermore, cells within 
alveolar walls showed both cytoplasmic and nuclear immunostaining. Although cells 
in alveolar walls could not defi nitely be identifi ed by histopathology many are large 
cells with irregular borders, abundant cytoplasm and large nuclei and are located within 
the interstitium and possibly within capillaries which suggests they could be interstitial 
macrophages or pulmonary intravascular macrophages.  
Vaccination with R345V reduces viral loads in the lung and nasal swabs
To evaluate the effi cacy of  R345V single dose vaccine administered by the intranasal 
route against H1N1 2009 MAFRI09 we isolated virus from apical and cardiac lobes 
and compared the viral loads between vaccinated and control pigs. Consistent with 
previous observations at necropsy, histopathology and IHC, a signifi cant reduction 
of  virus load by two to three orders of  magnitude was observed in vaccinated pigs 
compared to control pigs in both the apical and cardiac lung lobes (Fig. 3). Virus was 
recovered from cardiac lobes of  two vaccinated and challenged animals with the titers 
signifi cantly lower than in control challenged group (P=0.027 and P=0.047). RT-PCR 
analysis of  apical and cardiac lung lobe samples confi rmed the virus isolation results 
with a signifi cant (P=0.0195 and P=0.021) reduction of  viral RNA in vaccinated pigs 
compared to control pigs (Fig. 4). 
Figure 3. Lung virus titers. Lung tissues from 
the apical and cardiac lobes were homogenized 
and virus titers were determined on MDCK 
cells. Differences between vaccinated (R345V) 
pigs compared to control (MEM) pigs were de-
termined using a Mann-Whitney nonparametric 
t-test P < 0.05. The bar represents the median. 
The limit of  detection for the virus isolation 
was 2 log10/g and is a default value for samples 
below the limit of  detection.
Figure 4. Infl uenza viral genome copies in 
lungs. Lung tissues from the apical and cardiac 
lobes were homogenized and viral genome 
copies were determined by real time RT-
PCR assay. Differences between vaccinated 
(R345V) pigs compared to control (MEM) 
pigs were determined using a Mann-Whitney 
nonparametric t-test P < 0.05. The bar 
represents the median. The bar represents the 
median. The limit of  detection for the real time 
RT-PCR assay for lung homogenates was 4 
log10/g and is a default value for samples below 
the limit of  detection.
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RT-PCR was used to evaluate viral shedding in nasal swabs collected for fi ve consecutive 
days following challenge. Prior to challenge nasal swabs were collected from all pigs and 
were negative for infl uenza virus RNA. Viral RNA was detected by real-time RT-PCR 
at days two and three post challenge in 2 (day 2) and 1 (day 3) out of  5 vaccinated pigs 
(Fig. 5). In contrast, non-vaccinated control pigs following H1N1 2009 challenge had 
detectable viral RNA during the all fi ve days post challenge (Fig. 5). Vaccination with 
R345V signifi cantly reduced (P=0.0067) the levels of  potential virus shedding from 
upper respiratory tract determined by the presence of  viral RNA detected by RT-PCR 
in nasal swabs.
Serology following single vaccination of R345V
Prior to vaccination all pigs were negative for infl uenza specifi c antibodies as determined 
by IDEXX, cELISA and VNT against H1N1 2009. Fifteen days following intranasal 
vaccination with the R345V, all 5 pigs generated anti-infl uenza virus antibodies 
assessed using the IDEXX and cELISA (data not shown) but had no any detectable 
neutralizing antibodies against H1N1 2009 (Fig. 6). Unvaccinated control pigs did not 
have and infl uenza specifi c antibodies prior to challenge. Five days post challenge, 
signifi cant levels of  neutralizing antibodies to H1N1 2009 were detected in sera of  
all fi ve vaccinated pigs whereas unvaccinated control pigs did not develop signifi cant 
neutralizing antibodies (Fig. 6). 
Figure 5. Infl uenza viral genome copies in nasal swabs. Nasal swabs were collected prior to and 
daily following H1N1 2009 challenge (A) in vaccinated and (B) unvaccinated control pigs; viral 
genome copies were determined by real time RT-PCR assay. The bar represents the median. The 
limit of  detection for the real time RT-PCR assay for swabs was 3 log10/ml and is a default value 




The main advantage of  LAIV compared to their inactivated counterparts is the induction 
of  both cell-mediated (CMI) and antibody mediated immunity at the site of  infection 
that resemble the natural infection [16]. The activation of  CMI and strong mucosal 
antibody response are crucial in developing long-lived cross-protective immunity 
against infl uenza A virus infections. However, the major regulatory issue in the use of  
live attenuated viruses as vaccines is the possibility of  its reversion of  pathogenicity and 
reassortment with current wild type viruses. This gene exchange could possibly lead to 
the generation of  new circulating viruses with the potential in emerging to pandemic 
viruses. In order to mitigate this issue, the virus attenuated to generate the vaccine 
should be comprised of  viral genes of  low virulence.
With the elastase-dependent LAIV vaccine model the general fear that the HA gene 
of  LAIV would revert and reassort into circulating viruses was prevented by genetic 
modifi cation of  HA within cleavage site [15,26]. Using the well-established molecular 
techniques, infl uenza viruses with modifi ed cleavage site can be easily engineered and 
rapidly propagated in vitro in the presence of  the appropriate proteases [15,26,27]. The 
mutation within HA cleavage site serve as an attenuation phenotype which could be 
inherited by the wild type virus in the case of  reassortant leading to the attenuation of  
the wild type virus. In addition, the elastase enzyme is present in limited quantities in 
sites where the virus replicates in vivo, thus virus replication is also restricted. This limited 
Figure 6. H1N1 2009 neutralizing antibody titers. Prior to 
(15 DPI) and 5 days following H1N1 2009 challenge (20 DPI) 
sera from vaccinated (R345V) and control pigs (MEM) were 
evaluated for H1N1 2009 neutralizing antibodies. Differences 
between vaccinated (R345V) pigs compared to control (MEM) 
pigs following H1N1 challenge were determined using a Mann-
Whitney nonparametric t-test P < 0.05. The bar represents the 
median.
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replication is important as it decreases the probability of  any mutation or reassortment 
with any wild type virus making this LAIV a safer candidate.
Previously we demonstrated that R345V an elastase-dependent non-homologous H1N1 
vaccine administered twice either by the intranasal or intratreacheal routes was able 
to reduce lung pathology, virus replication and virus shedding following H1N1 2009 
challenge  [14]. In the current study, it was investigated whether the R345V elastase-
dependent SIV is capable of  providing protection against H1N1 2009 SIV following a 
single intranasal vaccination. The result of  this study demonstrate that despite restricted 
replication and short antigen exposure, R345V SIV cleavage mutant showed signifi cant 
immunogenicity and the ability to protect against heterologous H1N1 SIV challenge 
following a single intranasal administration.  The R345V elastase-dependent non-
homologous H1N1 vaccine administered once by the intranasal route was able to reduce 
lung pathology, virus replication and virus shedding following H1N1 2009 challenge. 
The gross pathology along with histopathology, IHC results, virus isolation and real-
time RT-PCR results from upper and lower respiratory tract indicated that the single 
dose vaccination with R345V signifi cantly reduces viral replication following H1N1 
2009 challenge and is close to generating sterile immunity. In addition, the elastase-
attenuated vaccine was able to reduce viral shedding in nasal swabs of  vaccinated pigs 
which is critical to reduce infl uenza transmission and evolution in the fi eld. 
Cross-neutralizing antibodies to H1N1 2009 were detected only following challenge with 
H1N1 2009. This observation was not unexpected since it was previously demonstrated 
that following a single vaccination with R345V administered by the intratracheal or 
intranasal route rarely induced detectable cross-neutralizing antibodies. Although 
neutralizing antibodies are important in preventing infl uenza virus infection, the results 
demonstrate remarkable protection in R345V vaccinated pigs to H1N1 2009 challenge 
in the absence of  specifi c neutralizing antibodies against H1N1 2009. Protection in the 
absence of  cross-neutralizing antibodies indicates that factors such as non-neutralizing 
antibodies may be important in the clearance of  infl uenza virus by macrophages. 
Furthermore, cell mediated immunity against infl uenza is likely a key component in 
controlling infl uenza virus replication and providing cross-protection. Previously we 
demonstrated that R345V elastase-dependent SIV elicited signifi cant infl uenza specifi c 
cell mediated immunity, detected by the induction of  IFN-γ secreting cells from cells 
in the draining lymph nodes following primary and secondary immunizations [10,13]. 
Live attenuated infl uenza vaccines that can elicit broad protection against non-
homologous infl uenza viruses of  the same type, combined with biosecurity and 
surveillance, would enhance pandemic preparedness against newly emerging infl uenza. 
The development of  several live attenuated infl uenza viruses covering the HA subtypes 
that have the pandemic potential, would enhance infl uenza pandemic preparedness. 
Since the vaccine can be manufactured prior to the emergence of  a new infl uenza 
virus and then tested for effi cacy immediately without having to develop and produce 
a new vaccine.  The demonstration of  vaccine effi cacy following single intranasal 
administration is a major step to application of  this vaccine in the fi eld. Further fi eld 
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VAKCINACIJA SA JEDNOM DOZOM ELASTAZA-ZAVISNOG ŽIVOG 
ATENUIRANONG H1N1 VIRUSA INFLUENCE SVINJA OBEZBEĐUJE 
DOVOLJNU ZAŠTITU PROTIV 2009 PANDEMIČNOG H1N1 VIRUSA 
KOD SVINJA
MAŠIĆ Aleksandar, WOLDEAB Niziti, EMBURY-HYATT Carissa, ZHOU Yan, 
BABIUK Shawn
Pandemija izazvana virusom infl uence A tipa H1N1 u 2009. godini, istakla je značaj 
svinja u evoluciji virusa infl uence A i pojavu novih virusa sa pandemijskim potencijalom. 
Takođe, infekcije virusom infl uence A značajno doprinose smanjenju proizvodnje u 
poljoprivrednoj industriji što za rezultat ima povećanje gubitaka i značajan pad profi ta. 
Primarni metod za kontrolu virusnih infekcija izazvanih virusom infl uence A kod svinja 
je putem vakcinacije. Prethodno smo demonstrirali da dve doze elastaza-zavisnog, živog 
atenuiranog virusa infl uence svinja date intratrahealno ili intranazalno mogu da obezbede 
visok stepen zaštite svinja od novih infekcija sa homolognim i različitim heterologim 
virusima infl uence svinja. U ovom radu smo opisali efi kasnost vakcinacije jedne doze 
elastaza-zavisnog, živog atenuiranog virusa infl uence svinja, date intranazalno, protiv 
infekcije sa homolognim 2009 pandemičnim virusom subtipa H1N1. Zaštita protiv 
H1N1 2009 virusa kod vakcinisanih svinja je primećena i u odsustvu neutralizacionih 
antitela u serumu specifi čnih za H1N1 2009 virus.
